Arecor Therapeutics (LSE:AREC) Cash Flow from Financing : £-0.18 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Arecor Therapeutics paid £0.00 Mil more to buy back shares than it received from issuing new shares. It received £0.04 Mil from issuing more debt. It paid £0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received £0.00 Mil from paying cash dividends to shareholders. It spent £0.01 Mil on other financial activities. In all, Arecor Therapeutics earned £0.03 Mil on financial activities for the six months ended in Dec. 2023.

Arecor Therapeutics Cash Flow from Financing Historical Data

The historical data trend for Arecor Therapeutics's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics Cash Flow from Financing Chart

Arecor Therapeutics Annual Data

Trend

May17

May18

May19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

Get a 7-Day Free Trial

5.32

1.77

20.93

5.16

-0.18

Arecor Therapeutics Semi-Annual Data
	May18	May19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash Flow from Financing	Get a 7-Day Free Trial					-0.07	-0.07	5.23	-0.12	-0.06

Arecor Therapeutics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Arecor Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0.038	+	0	+	0	+	-0.015
=	0.02

Arecor Therapeutics's Cash from Financing for the quarter that ended in Dec. 2023 is:

	Cash Flow from Financing		(Q: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0.038	+	0	+	0	+	-0.005
=	0.03

Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.18 Mil.

Arecor Therapeutics (LSE:AREC) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Arecor Therapeutics's issuance of stock for the six months ended in Dec. 2023 was £0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Arecor Therapeutics's repurchase of stock for the six months ended in Dec. 2023 was £0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Arecor Therapeutics's net issuance of debt for the six months ended in Dec. 2023 was £0.04 Mil. Arecor Therapeutics received £0.04 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Arecor Therapeutics's net issuance of preferred for the six months ended in Dec. 2023 was £0.00 Mil. Arecor Therapeutics paid £0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Arecor Therapeutics's cash flow for dividends for the six months ended in Dec. 2023 was £0.00 Mil. Arecor Therapeutics received £0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Arecor Therapeutics's other financing for the six months ended in Dec. 2023 was £-0.01 Mil. Arecor Therapeutics spent £0.01 Mil on other financial activities.

Arecor Therapeutics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Arecor Therapeutics (LSE:AREC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

6UI:Germany

Address

Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL

Website

https://www.arecor.com

Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.